Occupational airborne contact dermatitis from diphencyprone in a pharmacy employee

Bircher, Andreas J.; Bigliardi, Paul L.; Messmer, S. Langauer; Surber, Christian

doi:10.1111/j.1600-0536.1999.tb06217.x

Cited by 18 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermatitis in chemists handling pure DPCP was recognized in the early 1970s 51,53 , 54 and a recent case occurred in a chemist analysing an organotin product containing DPCP as a tin salt ligand 55 . Sensitization of pharmacy, medical and nursing staff involved in its preparation and use is a potential hazard 56–58 …”

Section: Introductionmentioning

confidence: 99%

“…Staff should be well trained in handling of the chemical and should wear protective latex or vinyl gloves for all parts of the procedure, 57 including disposal of contaminated equipment (in our department we place the used cotton buds into ‘sharps’ containers). Sensitization of pharmacy, nursing and medical staff is a well‐documented hazard 51 , 55–58,71 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The therapeutic use of topical contact sensitizers in benign dermatoses

Buckley

Vivier

2008

British Journal of Dermatology

View full text Add to dashboard Cite

Topical therapy using contact sensitizers has been practised since the 1960s to treat conditions associated with an altered immunological state. Dinitrochlorobenzene, squaric acid dibutyl ester and diphencyprone are most commonly employed in the therapy of alopecia areata and viral warts. Few dermatology departments in the U.K. provide such treatment. This systematic review discusses the various contact sensitizers used for topical immunotherapy, the methodology of treatment, factors influencing efficacy and likely adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The therapeutic use of topical contact sensitizers in benign dermatoses

Buckley

Vivier

2008

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…These include urticaria [169][170][171][172][173][174][175][176][177], depigmentation [155,156,160], vitiligo [150-154, 157-159, 178], erythema multiforme [179][180][181][182][183], discoid lupus erythematosus [184,185], angioedema [186,187], nickel sensitivity [188], allergic contact dermatitis from dyes in wigs [189], acquired hair curling [190], hair pigmentary changes [191], psoriatic koebnerization [192], pityriasis lichenoides [193], dyspepsia [173], epidermolysis bullosa acquisita [194], and anaphylaxis [195]. In addition, there are a few reports documenting sensitization to the medical staff that handle the chemical compound [196][197][198][199][200][201]. Appropriate precautions are strongly recommended when using or preparing the substance, such as a designated area with adequate ventilation, protective garments, and facilities for storage.…”

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract